Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study

被引:30
|
作者
Chiaravalloti, Agostino [1 ,2 ]
Barbagallo, Gaetano [3 ]
Ricci, Maria [4 ]
Martorana, Alessandro [5 ,6 ]
Ursini, Francesco [7 ]
Sannino, Pasqualina [2 ]
Karalis, Georgios [1 ]
Schillaci, Orazio [1 ,2 ]
机构
[1] Univ Tor Vergata, Dept Biomed & Prevent, Viale Oxford 81, I-00133 Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
[3] Magna Graecia Univ Catanzaro, Inst Neurol, Catanzaro, Italy
[4] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
[5] Univ Tor Vergata, Dept Neurosci, Rome, Italy
[6] IRCCS Santa Lucia, Rome, Italy
[7] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy
关键词
Alzheimer; PET; CSF; Tau; Brain imaging; CEREBROSPINAL-FLUID BIOMARKERS; POSITRON-EMISSION-TOMOGRAPHY; OSTERRIETH COMPLEX FIGURE; GLUCOSE-METABOLISM; OLFACTORY STIMULATION; DIAGNOSTIC-ACCURACY; EARLY-ONSET; DEPOSITION; HYPOMETABOLISM; INVOLVEMENT;
D O I
10.1016/j.brainres.2017.10.016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especially the role of amyloid beta and tau pathology in the development of the disease are still matter of debate. Changes in tau and amyloid beta peptide concentration in cerebrospinal fluid (CSF) and hypometabolic patterns at fluorine-18 fluorodeoxyglucose (F-18-FDG) PET scanning are considered as biomarkers of AD. The present study was aimed to evaluate the relationships between the concentrations of CSF total Tau (t-Tau), phosphorilated Tau (p-Tau) and A beta(1-42) amyloid peptide with F-18-FDG brain distribution in a group of patients with AD. Materials and methods: We examined 131 newly diagnosed AD patients according to the NINCDS-ADRDA criteria and 20 healthy controls. The mean (+/- SD) age of the patients was 70 (+/- 7) years; 57 were male and 74 were female. All patients and controls underwent a complete clinical investigation, including medical history, neurological examination, mini-mental state examination (MMSE), a complete blood screening (including routine exams, thyroid hormones and a complete neuropsychological evaluation). Structural MRI was performed not earlier than 1 month before the F-18-FDG PET/CT. The following patients were excluded: those with isolated deficits and/or unmodified MMSE (= 25/30) on revisit (period of follow-up: 6, 12 and 18 months); patients who had had a clinically manifest acute stroke in the last 6 months with a Hachinsky score greater than 4; and patients with radiological evidence of subcortical lesions. All AD patients were taken off cholinesterase inhibitor treatment throughout the study. We performed lumbar puncture and CSF sampling for diagnostic purposes 2 weeks (+/- 2 days) before the PET/CT scan. The relationship between brain F-FDG uptake and CSF biomarkers was analysed using statistical para-metric mapping (SPM8; Wellcome Department of Cognitive Neurology, London, UK) implemented in Matlab R2012b using the MMSE score, sex and age, and other CSF biomarkers as covariates. Results: t-Tau, p-Tau and A beta(1-42) in CSF resulted 774 +/- 345 pg/ml, 98 +/- 64 pg/ml and 348.8 +/- 111 pg/ml respectively. SPM analysis showed a significant negative correlation between CSF t-Tau and F-18 FDG uptake in right temporal, parietal and frontal lobe (Brodmann areas, BA, 20, 40 and 8; P fdr and few co rr < 0.001, ke 19534). We did not find any significant relationships with other CSF biomarkers. Conclusions: t-Tau deposition in brain is related to temporal, parietal and frontal hypometabolism in AD. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:116 / 122
页数:7
相关论文
共 50 条
  • [1] Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease
    Leuzy, Antoine
    Cicognola, Claudia
    Chiotis, Konstantinos
    Saint-Aubert, Laure
    Lemoine, Laetitia
    Andreasen, Niels
    Zetterberg, Henrik
    Ye, Keqiang
    Blennow, Kaj
    Hoeglund, Kina
    Nordberg, Agneta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1152 - 1163
  • [2] Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers
    Ossenkoppele, Rik
    Reimand, Juhan
    Smith, Ruben
    Leuzy, Antoine
    Strandberg, Olof
    Palmqvist, Sebastian
    Stomrud, Erik
    Zetterberg, Henrik
    Scheltens, Philip
    Dage, Jeffrey L.
    Bouwman, Femke
    Blennow, Kaj
    Mattsson-Carlgren, Niklas
    Janelidze, Shorena
    Hansson, Oskar
    EMBO MOLECULAR MEDICINE, 2021, 13 (08)
  • [3] Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
    Antoine Leuzy
    Claudia Cicognola
    Konstantinos Chiotis
    Laure Saint-Aubert
    Laetitia Lemoine
    Niels Andreasen
    Henrik Zetterberg
    Keqiang Ye
    Kaj Blennow
    Kina Höglund
    Agneta Nordberg
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1152 - 1163
  • [4] Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings
    Tolboom, Nelleke
    Koedam, Esther L. G. E.
    Schott, Jonathan M.
    Yaqub, Maqsood
    Blankenstein, Marinus A.
    Barkhof, Frederik
    Pijnenburg, Yolande A. L.
    Lammertsma, Adriaan A.
    Scheltens, Philip
    van Berckel, Bart N. M.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2010, 24 (03) : 303 - 307
  • [5] Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer's Disease: A CSF/18F-FDG-PET Study
    Bonomi, Chiara Giuseppina
    Chiaravalloti, Agostino
    Camedda, Riccardo
    Ricci, Francesco
    Mercuri, Nicola Biagio
    Schillaci, Orazio
    Koch, Giacomo
    Martorana, Alessandro
    Motta, Caterina
    BIOMEDICINES, 2023, 11 (03)
  • [6] CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
    Buerger, Katharina
    Ewers, Michael
    Pirttila, Tuula
    Zinkowski, Raymond
    Alafuzoff, Irina
    Teipel, Stefan J.
    DeBernardis, John
    Kerkman, Daniel
    McCulloch, Cheryl
    Soininen, Hilkka
    Hampel, Harald
    BRAIN, 2006, 129 : 3035 - 3041
  • [7] Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease
    Tabuas-Pereira, Miguel
    Duraes, Joao
    Lopes, Joana
    Sales, Francisco
    Bento, Conceicao
    Duro, Diana
    Santiago, Beatriz
    Almeida, Maria Rosario
    Leitao, Maria Joao
    Baldeiras, Ines
    Santana, Isabel
    EPILEPSY & BEHAVIOR, 2019, 98 : 207 - 209
  • [8] Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease
    Tanner, Jeremy A.
    Iaccarino, Leonardo
    Edwards, Lauren
    Asken, Breton M.
    Gorno-Tempini, Maria L.
    Kramer, Joel H.
    Pham, Julie
    Perry, David C.
    Possin, Katherine
    Malpetti, Maura
    Mellinger, Taylor
    Miller, Bruce L.
    Miller, Zachary
    Mundada, Nidhi S.
    Rosen, Howard J.
    Soleimani-Meigooni, David N.
    Strom, Amelia
    La Joie, Renaud
    Rabinovici, Gil D.
    BRAIN, 2022, 145 (12) : 4489 - 4505
  • [9] Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
    Leuzy, Antoine
    Bollack, Ariane
    Pellegrino, Daniela
    Teunissen, Charlotte E.
    La Joie, Renaud
    Rabinovici, Gil D.
    Franzmeier, Nicolai
    Johnson, Keith
    Barkhof, Frederik
    Shaw, Leslie M.
    Arkhipenko, Alexander
    Schindler, Suzanne E.
    Honig, Lawrence S.
    Moscoso Rial, Alexis
    Scholl, Michael
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Farrar, Gill
    ALZHEIMERS & DEMENTIA, 2025, 21 (03)
  • [10] CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
    Blennow, K
    Vanmechelen, E
    Hampel, H
    MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) : 87 - 97